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Abstract
Gut motility is modulated by adrenergic mechanisms. The aim of our study was to examine mechanisms of selective
adrenergic receptors in rat jejunum. Spontaneous contractile activity of longitudinal muscle strips from rat jejunum was
measured in 5-ml tissue chambers. Dose–responses (six doses, 10−7–3 × 10−5M) to norepinephrine (NE, nonspecific),
phenylephrine (PH, α1), clonidine (C, α2), prenalterol (PR, β1), ritodrine (RI, β2), and ZD7714 (ZD, β3) were evaluated
with and without tetrodotoxin (TTX, nerve blocker). NE(3 × 10−5M) inhibited 74 ± 5% (mean ± SEM) of spontaneous
activity. This was the maximum effect. The same dose of RI(β2), PH(α1), or ZD(β3) resulted in an inhibition of only 56 ± 5,
43 ± 4, 33 ± 6, respectively. The calculated concentration to induce 50% inhibition (EC50) of ZD(β3) was similar to NE,
whereas higher concentrations of PH(α1) or RI(β2) were required. C(α2) and PR(β1) had no effect. TTX changed
exclusively the EC50 of RI from 4.4 ± 0.2 to 2.7 ± 0.8% (p < 0.04). Contractility was inhibited by NE (nonspecific). PH
(α1), RI(β2), and ZD(β3) mimic the effect of NE. TTX reduced the inhibition by RI. Our results suggest that muscular α1,
β2, and β3 receptor mechanisms mediate adrenergic inhibition of contractility in rat jejunum. β2 mechanisms seem to
involve also neural pathways.
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Introduction
The modulation of gastrointestinal muscular activity is
dependent on the interaction of two complex neural
networks, the central nervous system with the extrinsic
nerves (vagal, sympathetic) that connect with the enteric
nervous system, which is completely intrinsic within the
bowel wall.1 In the gastrointestinal tract, interaction
between the central nervous system and the enteric nervous
system is important for the response to stress, for eating,
and for behavior.2
The upper gastrointestinal tract and the distal colon
and rectum are mainly modulated by vagal motor path-
ways. In the small bowel, vagal input is supplied to
myenteric neurons,3 which influence the generation of
motor patterns.
The nerve cell bodies of the intestinal sympathetic
nervous system are located in the prevertebral ganglia,
and enter the gut with their postganglionic fibers. In the gut
wall, no adrenergic nerve cell bodies are present.1 Most if
not all sympathetic postganglionic fibers affecting motility
are thought to synapse in the enteric nervous system and
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not directly on smooth muscle cells. Indeed, no synapses
exist between adrenergic nerves and the nonsphincter
muscle cells in the gut.4 In earlier research, despite the
predominant, direct adrenergic input to the enteric nervous
system, we found strong, adrenergic inhibitory motor
mechanisms in rat jejunum and ileum occurring preferen-
tially at the level of these smooth muscle cells rather than in
the enteric nervous system;5,6 these effects appeared to be
independent of input from the enteric nervous system.
Directing pharmacologic therapy at the receptors occur-
ring on smooth muscle cells in the gut could therefore be
one approach to target gastrointestinal motility disorders
through adrenergic pathways. Up to now, treatments
targeting adrenergic pathways in the gastrointestinal tract
have not been successful. One reason is that the agents used
produce substantial cardiovascular side effects.7 Therefore,
mechanisms and pathways of specific subtypes of adrener-
gic receptors involved in modulating contractile activity of
the gut are of considerable interest.
The effect of selective stimulation of β-adrenergic
receptors, especially the effect of β3 receptor agonists on
contractile activity in rat jejunal longitudinal muscle, has
not yet been examined. In the rat ileum, we previously
showed the importance of β3 receptor mechanisms for
contractile activity.8
In the current study, our first aim was to identify the
effect of the stimulation of all subtypes of adrenergic
receptors on jejunum longitudinal smooth muscle of the rat.
Our second aim was to determine if these receptor-specific
mechanisms were mediated at the level of the smooth
muscle and/or via the enteric nervous system. Our
hypothesis, based also on our findings in the rat ileum,8
was that α1, β2, and β3 receptor mechanisms all mediate
inhibitory responses and that these mechanisms are active
directly at the level of the smooth muscle and not indirectly
via effects mediated through the enteric nervous system.
Materials and Methods
Preparation of Tissue
Procedures and animal care were performed according to
the guidelines of the Department of Agriculture of the
Canton of Bern, Switzerland. Male Wistar rats were used in
all experiments. Anesthesia was achieved by intraperitoneal
sodium pentobarbital (5mg/100g; Abbott Laboratories,
North Chicago, IL). A 5-cm segment of the jejunum was
removed, beginning 2cm anal to the ligament of Treitz, and
stored in cold Krebs-Ringer’s buffer (concentration in mM:
NaCl 118.3, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2,
NaHCO3 25.0 calcium disodium edetate 0.26, and glucose
11.1). The proximal end of the specimen was marked.
Recording of Contractile Activity
The segment of the proximal jejunum was immersed in
chilled, modified Krebs–Ringer’s bicarbonate solution and
opened along the mesenteric border. The tissue was pinned
flat in a Petri dish, and eight full-thickness muscle strips
per rat were prepared in the direction of the longitudinal
muscle layer. Silk loops were tied at both ends of the
strips. The muscles were suspended vertically in 5-ml
organ chambers (Radnoti Glass Technology, Monrovia,
CA) filled with modified Krebs–Ringer’s bicarbonate
solution maintained at 37.5°C. The solution was bubbled
with 95% O2 and 5% CO2 (Carbagas, Bern, Switzerland).
The lower end of the muscle strip was connected to a fixed
glass hook in the chamber, while the upper end was
attached to a noncompliant force transducer (Radnoti
Glass Technology), thereby allowing measurement of
isometric force.
Experimental Design
After an equilibration period of 80–90min, with buffer
solution changed every 20–25min, each strip was stretched
incrementally at 10–15-min intervals to its optimal length
(Lo). Lo is defined as the length beyond which further
stretching did not increase the amplitude of spontaneous
contractions. The entire experiment was then performed at
this Lo; strips without spontaneous activity were not used
(2% of all muscle strips).
After baseline spontaneous activity was recorded, one
substance per chamber was administered in a cumulative
manner. Norepinephrine (NE) was chosen as the nonselec-
tive adrenergic agonist, phenylephrine and clonidine as α1-
and α2-selective agonists, and prenalterol, ritodrine, and
ZD7114 as β1-, β2-, β3-selective agonists, respectively.
Drugs were added in six cumulative doses (range 1 × 10−7–
3 × 10−5M) every 10min. The highest dose used was 3 ×
10−5M, according to our previous work using only NE.5,6
One chamber contained a control strip to confirm stable
activity for the duration of the experiment, and the last
chamber contained a spare strip.
After the dose–response experiment, the chambers were
washed four times with modified Krebs–Ringer’s buffer.
When spontaneous contractions returned to baseline activ-
ity, tetrodotoxin (TTX; 1 × 10–6M) was added to every
chamber. TTX is thought to abolish almost all enteric
neural input by blocking neuronal sodium channels. After a
15–20-min equilibration period, the same dose–response
experiment was repeated in each chamber with the same
agonist.
At the conclusion of the experiment, the length of each
strip between the two ties of silk loops and wet weight were
measured.
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Data Analysis
Total spontaneous contractile activity was quantified as the
integral of the generated force (g × time as total area under
the contractile curve) measured for 5min at Lo, while
responses to adrenergic agonists were quantified by
measuring the integral of force for 5min immediately after
drug administration. The integral of force was calculated
by computerized methodology using a special software
(AcqKnowledge, Biopac Systems, Goleta, CA), normal-
ized per millimeter squared of cross-sectional area (CSA)
for each muscle strip.
The CSA was calculated using the following equation:
CSA mm2
  ¼ tissue wet weight mgð Þ=tissue length mmð Þ
 tissue density mgmm3 
Tissue length and weight were measured at the end of the
experiment, and smooth muscle tissue density was assumed
to be 1.05mg/mm3.9
The dose–response curve for each agonist was obtained
by defining spontaneous contractile activity as 100%. To
quantify these dose–response curves, the negative of the
natural log (ln) of the equipotent concentration that caused
a 50% response (EC50) was estimated for each agonist
based on the dose–response curve. A greater EC50
represents a smaller concentration of an agonist needed to
induce 50% inhibition of spontaneous activity.
Values are presented as mean ± standard error of the
mean (SEM). Student’s t tests with a Bonferroni correction
were used to compare the effects of each specific agonist
with spontaneous activity at all doses and the respective
effect of NE. The effect of TTX on spontaneous activity, on
EC50, and on each dose of the respective agonist was
evaluated in the same way.
Changes of the amplitude were analyzed as follows. The
amplitude after the highest dose of each agonist without
TTX was calculated as a percentage of the amplitude at Lo.
After the second dose–response with a neural blockade, the
amplitude after the highest dose was calculated as a
percentage of the amplitude after the equilibration with
TTX (LoTTX).
Drugs
L-Phenylephrine hydrochloride, clonidine hydrochloride,
ritodrine hydrochloride, and NE bitartarate salt were
purchased from Sigma (St. Louis, MO). Prenalterol and
ZD7114 hydrochloride were purchased from Astra Zeneca
(Södertälje, Sweden). TTX was purchased from Juro
(Luzern, Switzerland).
Results
Spontaneous Contractile Activity
Spontaneous phasic contractile activity was recorded
shortly after suspending the muscle strips in the organ
chambers. After the addition of TTX (after the first
adrenergic dose–response experiments, washout, and resto-
ration of spontaneous activity), contractile activity remained
the same (92.7 ± 4 to 88.1 ± 4g/5min/mm2; p > 0.05).
Effect of Nonselective Adrenergic Stimulation
In all strips treated with NE, the amplitude and the baseline
tone were reduced in a dose-dependent manner, while the
frequency of contractions remained unchanged. At the
higher doses, an initial increase in basal tone was observed
(Fig. 1a). Inhibition of spontaneous contractile activity
induced by the highest dose of NE (3 × 10−5M) was 73.7 ±
5%. Blocking all neural activity within the bowel wall with
TTX (1 × 10−6M) changed neither the dose response to NE
(Table 1) nor the effect of the highest dose of NE on the
reduction in the amplitude (Table 2).
Effect of α-Agonists
Phenylephrine (α1-agonist) inhibited contractile activity by
reducing the area under the curve but not the basal tone in a
dose-dependent fashion (Fig. 1). However, the EC50 was
less than for NE, and the inhibition (at 3 × 10–5 M) was less
compared to an equimolar dose of NE (Table 1; Figs. 1 and
2a). TTX had no effect on α1 receptor-mediated inhibition
induced by phenylephrine. Neither the reduction in the area
under the curve nor the change of basal tone was dependent
10 min
Norepinephrine
Phenylephrine
ZD7114
Ritodrine
0.2 g
a
b
c
d
10-7 3*10-7 10-6 3*10-6 10-5 3*10-5 M
Figure 1 Effect of a norepinephrine, b phenylephrine (α2),
c ritodrine (β2), and d ZD7114 (β3) on spontaneous activity.
Cumulatively administered molar doses of agents caused a dose-
dependent decrease in contractile activity.
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on presynaptic mechanisms (Tables 2 and 3). Clonidine
(α2-agonist) with and without TTX had no demonstrable
effect on contractile activity.
Effect of β-Agonists
Differing effects of the three β-adrenergic agonists were
noted. Prenalterol (β1-agonist) with or without TTX had no
effect. In contrast, ritodrine (β2-agonist) and ZD7114 (β3-
agonist) both induced a marked dose-dependent inhibition of
56 ± 5 and 44 ± 10% at the highest dose (3 × 10−5M),
respectively (Table 1, Fig. 2b). At smaller concentrations, the
inhibition induced by ZD7114 was even stronger compared
to NE (Fig. 2b). TTX did not influence the dose–response of
ZD7114 (β3-agonist), but it decreased the inhibition of
ritodrine (β2-agonist). This effect seems to be due primarily
to a smaller reduction in the amplitude. (Tables 2 and 3, Fig.
3). Ritodrine without TTX (3 × 10−5M; β2-agonist) reduced
the amplitude by 60 ± 6% compared to the amplitude at Lo.
In the presence of TTX, the reduction in the amplitude was
smaller (43 ± 5%, p < 0.05).
The EC50 for ZD7114 did not differ from the EC50 for
NE (5.8 ± 2 vs 5.6 ± 0.2, p > 0.05), suggesting a similar
molar inhibitory effect of ZD7114. However, the EC50 of
ritodrine and NE (4.4 ± 0.2 vs 5.0 ± 0.3, p < 0.05) differed,
Table 2 Reduction in Amplitude Induced by Adrenergic Agonist
without or with Tetrodotoxin (TTX; 10−6 M)
Response to 3×10−5M dosea
Without TTX With TTX
Norepinephrine 33±8 15±2**
Phenylephrine, α1 79±4 85±5
Clonidine, α2 91±6 99±4
Prenalterol, β1 100±10 97±12
Ritodrine, β2 40±6 57±5*
ZD7114, β3 80±6 66±6
*p<0.05 vs without TTX
**p=0.055 vs without TTX
aValues represent percent (mean±SEM; n=10 rats) of amplitude after
the highest dose of agonist (3×10−5 M) compared to the amplitude
before dose response experiment (100%).
Table 1 Inhibitory Effect of Selective Adrenergic Agonists on Rat Jejunal Longitudinal Muscle without and with Tetrodotoxin (TTX; 10–6M)
Response to 3 × 10−5M dosea EC50
without TTX with TTX without TTX with TTX
Norepinephrine 74 ± 5* 81 ± 4* 5.6 ± 0.2 5.8 ± 0.1
Phenylephrine, α1 α1 43 ± 4*
, ** 42 ± 5*, ** 1.9 ± 0.8** 2.2 ± 0.9**
Clonidine, α2 1 ± 9** 16 ± 5*
, ** NA NA
Prenalterol, β1 5 ± 6** 19 ± 4*
, ** NA NA
Ritodrine, β2 56 ± 5* 44 ± 10*
, ** 4.4 ± 0.2** 2.7 ± 0.8**, ***
ZD7114, β3 33 ± 6*
, ** 37 ± 7*, ** 5.8 ± 2 3.5 ± 0.4**
NA Not applicable, as no inhibition was seen
*p < 0.006 compared to spontaneous activity before adding respective drug
**p < 0.05 to NE
***p < 0.05 to EC50 without TTX
aValues: percent inhibition, mean ± SEM; n = 10 rats; EC50 represents calculated negative log of molar value resulting in 50% inhibition of
spontaneous activity.
LO 10-7 3*10-7 10-6 3*10-6 10-5 3*10-5 M
Concentration of α-adrenergic agonists
n=10 rats, mean± SEM, *p<0.05 vs NE
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Figure 2 Dose–responses of a clonidine (α1) and phenylephrine (α2)
and b prenalterol (β1), ritodrine (β2), and ZD7114 (β3) compared with
norepinephrine. Values represent percent mean±SEM (n=10 rats).
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suggesting that β2 receptors have a smaller influence. This
influence seems to decrease even more after TTX. The
dose–response curve of ritodrine under neural blockade
with TTX was shifted more to the right, and the EC50 was
2.7 ± 0.8, compared to 4.4 ± 0.2 for NE (p < 0.05; Fig. 2b).
These findings suggest that there is a neural β2 receptor-
dependent inhibitory pathway in rat longitudinal jejunum
smooth muscle.
Discussion
We designed our study to characterize the involvement of
specific adrenergic α1, α2, β1, β2, or β3 receptor
mechanisms in the inhibition of contractile activity of
longitudinal smooth muscle in the rat jejunum. As a
potential novel therapeutic target for motility disorders,
adrenergic pathways modulating gut motility are of partic-
ular interest. The identification of specific receptor subtype
mechanisms is required to target effects on intestinal
contractile function, possibly minimizing or even avoiding
cardiovascular side effects.
Our main findings were that α2 and β1 receptor
mechanisms do not appear to be involved in the adrenergic
modulation of gut contractile activity in the rat jejunum,
either directly on the smooth muscle cells or indirectly via
the enteric nervous system. In contrast, α1, β2, and β3
pathways reproduced, in part, the inhibition induced by NE,
a nonselective, global adrenergic agonist. Blocking enteric
neural activity within the muscle strip (with TTX, 10−6M)
reduced only the response of β2 receptor stimulation,
suggesting involvement of enteric neural mechanisms.
Because generally not much is known about the role of
α receptors in intestinal contractility, our results with the
involvement of α1 but not α2 receptors in inhibitory
modulation of motor activity in the rat jejunum are of
special interest. Similar to our findings, Fox et al.10
detected an inhibitory effect on contractile activity of α1
receptors in rat jejunum. In contrast to our results, Fox
et al.10 found an α2 receptor-mediated inhibition as well.
Another group documented the induction of neuronal nitric
oxide synthase expression after stimulation of α2 receptors
in rat jejunum, suggesting a potential inhibitory effect by α2
receptors, however, without physiologically measuring the
effect on contractile activity.11 Sagrada et al., 12 however,
measured an inhibitory influence on contractile activity of
α2 receptors as well as α1 receptors in rat jejunum. This
difference can be explained by the fact that they performed
an in vivo study where conditions and confounding effects
such as circulation are not controlled as well as in vitro in
tissue chambers.
Of greatest interest is a comparison of our results with
data from human studies. A case report of a patient with
pheochromocytoma, in whom paralytic ileus was treated
successfully with the α receptor antagonist phentolamine
and later with prazosin (a selective α1 receptor antago-
nist),13,14 suggests that α mechanisms may be involved in
human small bowel contractile activity. It is interesting to
note that α2 pathways did not seem to play a role in an in
vitro study in human tissue.14 Therefore, it seems likely
that the α-adrenergic influence in control of human small
bowel contractility is dependent on α1 receptors. This is in
accordance with our present results in the rat jejunum,
where α1 mechanisms but not α2 pathways appear to
influence contractile properties in vitro.
Generally, the role of α receptors seems to differ
between species and anatomical regions of the gut. In
a Ritodrine; b Ritodrine with TTX
10 min
0.2 g
10-7 3*10-7 10-6 3*10-6 10-5 3*10-5 M
a
b
Figure 3 a Effect of ritodrine (Rt; β2) on spontaneous activity.
Ritodrine was administered cumulatively and caused a dose-dependent
decrease in contractile activity. b In the presence of TTX, the dose-
dependent reduction in amplitude was smaller, thus reducing the
overall inhibitory effect induced by ritodrine.
Table 3 Reduction in Basal Tone Induced by Adrenergic Agonist
without or with Tetrodotoxin (TTX; 10−6 M)
Response to 3×10−5 M dosea
Without TTX With TTX
Norepinephrine 76±9 84±8
Phenylephrine, α1 51±7 49±11
Clonidine, α2 15±3 18±11
Prenalterol, β1 18±9 29±9
Ritodrine, β2 73±9 63±12
ZD7114, β3 64±7 63±12
a Values represent percent (mean±SEM; n=10 rats) reduction in the
baseline tone after the highest dose of agonist (3×10−5 M) compared
to the baseline tone before the dose–response experiment (100%).
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rabbit jejunum, only α1 but not α2 receptors mediate
inhibition,15,16 and in canine jejunum, equine jejunum,
and rat colon, only α2 but not α1 inhibitory mechanisms
have been described.17–21 We have previously shown
inhibitory α1 mechanisms in the rat ileum.
8 In rabbits, α1
mechanisms can be part of inhibitory pathways not only in
jejunum but in other anatomic regions of the gut as well.22
In our study, inhibitory mechanisms mediated by β2
adrenergic receptors were identified. These results are in
accordance with our findings in rat ileum, where β2
adrenergic receptors are an important part of inhibitory
mechanisms of adrenergic influence.8 The finding in the rat
jejunum is also consistent with results in rabbit jejunum,
23 whereas in canine jejunum, β2 pathways had no
influence on contractile activity.17 Fox et al.10 found an
inhibitory effect of β adrenergic receptors in rat jejunum
without conclusively assigning these mechanisms to spe-
cific subtypes of β adrenergic receptors.
Because β3 receptors seem to be abundantly present in
gastrointestinal tissue, they have been of particular interest.24,
25 Our results are in accordance with our previous study in rat
ileum 8 and with the data of Brown and Summers,26 where β3
pathways are shown to play a major role in the inhibition of
rat ileum. In the study of Fox et al.,10 β3 pathways could not
be selectively examined. Our results suggesting a major
inhibitory role of β3 mechanisms in rat jejunal smooth muscle
add important knowledge to rat gut contractile physiology.
In addition, we tried to distinguish between muscle-
related mechanisms and pathways involving the enteric
nervous system, as under pathologic conditions, adrenergic
mechanisms might be compromised at either level of
control.5,27,28 The pathways of the specific adrenergic α1,
α2, β1, or β3 receptor seem to be independent of the enteric
nervous system because none of these mechanisms were
sensitive to TTX. It is interesting to note that part of the β2
inhibition in our experiments appears to be modulated by
presynaptic mechanisms. Blockade of neural β2 mecha-
nisms by TTX resulted in less inhibition of contractile
activity. The neurally mediated effect appears to occur by a
decreased reduction in amplitude rather than a reduction in
baseline tone (Fig. 3). This finding is interesting, as it
differs from our results in the rat ileum, where the neural
part of β2 inhibitory mechanisms affected basal tone and
not amplitude. This might reflect a different β2-adrenergic
influence in the jejunum compared to the ileum, which is
conceivable because global motor patterns (i.e., myoelectric
motor complex) change their characteristics from oral to
aboral along the small bowel.29, 30
Our results are in contrast to the findings of Fox et al.,10
where presynaptic mechanisms are not involved in β-
adrenergic pathways. This difference could be explained by
a different approach of excluding neural input. While they
eliminated only the myenteric neurons with an application of
benzalkonium chloride to the bowel in an operation 15days
before the in vitro experiment, we treated the muscle strips
during the experiment with TTX, which represents an acute
near-complete abolishment of neural activity.
Whereas in other groups and study designs, no distinction
between muscle or neutrally mediated inhibition was made,31
we think that such findings are important. Considering
gastrointestinal motility disorders in neurological diseases such
as diabetic neuropathy or other postneurotomy syndromes (e.g.,
postvagotomy gastro paresis), it is possible that a lack of neural
input could result in impaired modulation of contractile activity
by β2 mechanisms. Thus, further studies are required.
Conclusion
We conclude that adrenergic inhibition in the rat jejunum
may be an additive effect of the three specific adrenergic
mechanisms noted to inhibit contractile activity (α1, β2,
and β3). None of the specific pathways alone reached the
degree of inhibition achieved by NE. Our previous data in
the rat ileum,8 other previous results in rabbit ileum,31 and
studies in human colon by Manara et al.32 support this
concept of the involvement of several receptors in inhibi-
tory mechanisms.
When we compare our results with the literature, not only
the high degree of regional variability (anatomic region and
muscle layer) but also differences between species is
striking. Regarding differences between anatomic regions,
we have now shown that receptor-specific adrenergic
inhibitory mechanisms seem to be similar in rat jejunum
and rat ileum. In comparison to the human gut, it is of
interest that α1 receptor mechanisms (but not α2 pathways)
played a role in our present rat jejunum and previous rat
ileum study.8 The scarce data from the literature suggest a
similar constellation of contractile α-adrenergic mechanisms
in human small bowel. If this similarity is confirmed in the
future, the rat small bowel might be attractive to further
model α1 pathways in pathologic states.
For β2 and β3 receptors, differences between species are
evident as well, but we do not have comparable data for
human jejunum. Species differences, especially for β3
pathways, would be of interest, as these receptors are
abundantly present in gastrointestinal tissue and are
therefore of interest for gastrointestinal motility.33,34 Our
findings of an important role of inhibitory β3 mechanisms
in rat jejunal contractile activity are novel and add to the
understanding of rat small bowel contractile properties.
Because we have shown that α-adrenergic mechanisms
seem to have a similar effect in the rat jejunum and in
human jejunum, in future studies, it will be of special
interest to address the similarities between rat and human
β3 pathways in jejunal smooth muscle.
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